Sign in

CLVS on NASDAQ

Clovis Oncology

American pharmaceutical company

Clovis Oncology is an American pharmaceutical company which mainly markets products for treatment in oncology. Clovis was founded in 2009 and is headquartered in Boulder, Colorado. The company is a publicly traded company on NASDAQ under the symbol CLVS and is in the NASDAQ Biotechnology Index with several products in its product pipeline.3 Wikipedia text CC BY-SA 4.0

Price unavailable

Last updated Oct 21, 2026.

Overview

2009Founded1

Compare with ELITE PHARMACEUTICALS INC /NV/, MACROGENICS INC or Karyopharm Therapeutics Inc., or pick any stock.

  • TickerCLVS on NASDAQ1
  • Industrypharmaceutical industry1
  • HeadquartersWilmington1
  • Websiteclovisoncology.com
  • Legal formpublic company1
  • Incorporated inDE5
  • Business address5500 Flatiron Parkway, Suite 100, Boulder, Co 803015
  • Filer categoryLarge accelerated filer5
  • LEI529900WCUY9ZAHMRV4894
  • StatusActive4
  • LEI statusLapsed (not renewed)4
  • Registered addressc/o THE CORPORATION TRUST COMPANY, CORPORATION TRUST CENTER 1209 ORANGE ST, 19801 Wilmington, United States4
  • Registered withDivision of Corporations, Department of State, 46783604

See how the biggest companies compare on our leaderboards

Clovis Oncology is an American pharmaceutical company which mainly markets products for treatment in oncology. Clovis was founded in 2009 and is headquartered in Boulder, Colorado. The company is a publicly traded company on NASDAQ under the symbol CLVS and is in the NASDAQ Biotechnology Index with several products in its product pipeline. As of December 31, 2017, the company was not profitable and had incurred losses in each year since its inception in April 2009. In December 2022, Clovis Oncology filed for Chapter 11 bankruptcy.3

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2021

-151.8%Operating margin7
-177.8%Net margin7
-9.6%Revenue growth, 20217
-$196.4MFree cash flow7

Where the money goes

Where each dollar of revenue went, fiscal 2021

  • Selling, general and admin86¢$128.4M
  • Other costs13¢$20.0M
  • Income tax0¢$404.0K

Out of $148.8M in revenue.7 The company lost money this year.

Financial statements

Revenue8910117$148.8M in 2021
0$50.0M$100.0M$150.0M$200.0M2015: $0$020152016: $78.0K$78.0K20162017: $55.5M$55.5M2017+71068%2018: $95.4M$95.4M2018+72%2019: $143.0M$143.0M2019+50%2020: $164.5M$164.5M2020+15%2021: $148.8M$148.8M2021−10%
Operating income12910117-$225.8M in 2021−40% since 2015
-$400.0M-$300.0M-$200.0M-$100.0M02015: -$376.7M-$376.7M20152016: -$372.7M-$372.7M2016−1%2017: -$237.6M-$237.6M2017−36%2018: -$333.8M-$333.8M2018+40%2019: -$376.7M-$376.7M2019+13%2020: -$302.2M-$302.2M2020−20%2021: -$225.8M-$225.8M2021−25%
Net income12910117-$264.5M in 2021−25% since 2015
-$600.0M-$400.0M-$200.0M02015: -$352.9M-$352.9M20152016: -$349.1M-$349.1M2016−1%2017: -$346.4M-$346.4M2017−1%2018: -$368.0M-$368.0M2018+6%2019: -$400.4M-$400.4M2019+9%2020: -$369.2M-$369.2M2020−8%2021: -$264.5M-$264.5M2021−28%
Fiscal year2015201620172018201920202021
Revenue$08$78.0K9$55.5M10$95.4M11$143.0M7$164.5M7$148.8M7
Cost of revenue$08$70.0K8
Selling, general and admin$30.5M12$40.7M9$138.9M10$175.8M11$182.8M7$163.9M7$128.4M7
Operating expenses$374.5M7
Operating income-$376.7M12-$372.7M9-$237.6M10-$333.8M11-$376.7M7-$302.2M7-$225.8M7
Interest
Income before tax-$264.9M7
Income tax-$29.1M12-$32.0M9-$3.6M10$608.0K11$1.8M7-$547.0K7-$404.0K7
Net income-$352.9M12-$349.1M9-$346.4M10-$368.0M11-$400.4M7-$369.2M7-$264.5M7
Earnings per share-$7.437-$4.387-$2.297
Earnings per share (diluted)-$7.437-$4.387-$2.297
Shares (weighted, basic)115.5M shares7
Shares (weighted, diluted)115.5M shares7

Compare Clovis Oncology with another company

Corporate structure

Clovis Oncology sits at the top of its group. 1 entity, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of Clovis Oncology

  • Clovis Oncology Wilmington, Delaware, United States

Built from parent and subsidiary links from GLEIF, the Global Legal Entity Identifier Foundation (CC0); major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What Clovis Oncology reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Property and equipment, before depreciation$18.0M7 Dec 31, 2021$23.1M7 Dec 31, 2020−22.2%
Accumulated depreciation$11.4M7 Dec 31, 2021$11.1M7 Dec 31, 2020+3.6%
Property and equipment, net$6.6M7 Dec 31, 2021$12.1M7 Dec 31, 2020−45.8%

Investments

ItemLatestA year beforeChange
Cash and cash equivalents$143.4M7 Dec 31, 2021$240.2M7 Dec 31, 2020−40.3%

Intangibles and goodwill

ItemLatestA year beforeChange
Goodwill$63.1M7 Dec 31, 2021$63.1M7 Dec 31, 20200%
Intangible assets, net (excluding goodwill)$60.4M7 Dec 31, 2021$65.7M7 Dec 31, 2020−8.2%

Inventory

ItemLatestA year beforeChange
Inventory, total$13.7M7 Dec 31, 2021$30.7M7 Dec 31, 2020−55.4%
Work in process$85.1M7 Dec 31, 2021$102.5M7 Dec 31, 2020−17.0%
Finished goods$38.5M7 Dec 31, 2021$32.3M7 Dec 31, 2020+18.9%

The story

Clovis Oncology was founded in 2009 by Patrick Mahaffy in Boulder, Colorado. The company was named in honor of the Mahaffy cache, a collection of Clovis period stone tools dated to 11,000 BCE, discovered in the front yard of Mahaffy's home in Boulder.

From Wikipedia’s article on Clovis Oncology, shared under CC BY-SA 4.0.6

Leadership

Who has led Clovis Oncology, and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Patrick J. Mahaffy2011–2020

President

  1. Patrick J. Mahaffy2011–2020

Chief financial officer

  1. Erle T. Mast2011–2015
2010201520202025
Board members and other officers (22)

Products and brands

Rociletinib

The company was developing rociletinib, as a treatment for non-small cell lung cancer. A phase III trial was completed in April 2016 and had it been approved it would have competed with AstraZeneca's Tagrisso (osimertinib). According to the company web site as of November 2016 studies on the drug are no longer accepting new patients, but Clovis would continue to supply the drug to patients whose physicians had recommended continued treatment.

In September 2018, the company and two former executives agreed to a $20 million settlement with the Securities and Exchange Commission on claims it exaggerated to investors the efficacy of Roci in patient trials.

Rucaparib

Rucaparib is a PARP inhibitor in Phase II and III clinical trials for advanced ovarian cancer. In December 2016, the Food and Drug Administration granted an accelerated approval for the use of rucaparib "for the treatment of patients with deleterious BRCA mutation (germline and/or somatic)-associated advanced ovarian cancer who have been treated with two or more chemotherapies". In 2023, rucaparib was sold to Pharmaand GmbH (Pharma&) as part of Clovis's bankruptcy proceedings.

Lucitanib

Lucitanib is a VEGFR inhibitor. It is also an inhibitor of FGFR1 and FGFR2 and has undergone clinical trials for advanced solid tumors.

From Wikipedia’s article on Clovis Oncology, shared under CC BY-SA 4.0.6

Timeline

  1. Jul 11, 20238-K Bankruptcy or receivership; Change to shareholders' rights; Change in control38
  2. Jun 30, 20238-K Change to shareholders' rights; Regulation FD disclosure39
  3. Jun 2, 20238-K Regulation FD disclosure; Other events40
  4. May 3, 20238-K Regulation FD disclosure41
  5. May 1, 20238-K Completed an acquisition or sale42
  6. Apr 14, 20238-K Completed an acquisition or sale43
  7. Apr 6, 20238-K Entered a material agreement44
  8. Mar 31, 20238-K Regulation FD disclosure45
  9. Mar 2, 20238-K Regulation FD disclosure46
  10. Feb 16, 20238-K Executive or director change47
  11. Feb 13, 20238-K Regulation FD disclosure; Other events48
  12. Jan 12, 20238-K Entered a material agreement; New debt or obligation49
  13. Nov 16, 2011Went public Listed on NASDAQ1
  14. Nov 15, 2011New chief executive Patrick J. Mahaffy becomes CEO15
  15. 2009Founded Founded1

Calendar

When it reported results

  1. Aug 8, 2022Reported quarterly or annual results50
  2. May 4, 2022Reported quarterly or annual results51
  3. Feb 23, 2022Reported quarterly or annual results52
  4. Jan 10, 2022Reported quarterly or annual results53
  5. Nov 3, 2021Reported quarterly or annual results54

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar

Filings

114 filings to the SEC since October 2021: 1 annual reports, 4 quarterly reports, 27 major events, 51 insider forms, 10 large holders, 21 other. The latest 20:

  1. Jul 17, 2023EFFECT EDGAR
  2. Jul 11, 202315-12G EDGAR
  3. Jul 11, 2023S-8 POS EDGAR
  4. Jul 11, 2023S-8 POS EDGAR
  5. Jul 11, 2023S-8 POS EDGAR
  6. Jul 11, 2023S-8 POS EDGAR
  7. Jul 11, 2023S-8 POS EDGAR
  8. Jul 11, 2023S-8 POS EDGAR
  9. Jul 11, 2023S-8 POS EDGAR
  10. Jul 11, 2023S-8 POS EDGAR
  11. Jul 11, 2023S-8 POS EDGAR
  12. Jul 11, 2023S-8 POS EDGAR
  13. Jul 11, 2023S-8 POS EDGAR
  14. Jul 11, 2023POS AM EDGAR
  15. Jul 11, 20238-K EDGAR
  16. Jun 30, 20238-K EDGAR
  17. Jun 2, 20238-K EDGAR
  18. May 3, 20238-K EDGAR
  19. May 1, 20238-K EDGAR
  20. Apr 14, 20238-K EDGAR

The 114 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

50 open-market trades by officers, directors and large owners since October 2021: 0 buys and 50 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Nov 2, 2022Gross Paul EdwardSee RemarksSale4,730$0.98$4.6KForm 4
Nov 2, 2022IVERS-READ GILLIAN CSee RemarksSale3,681$0.98$3.6KForm 4
Nov 2, 2022Harding Thomas C.See RemarksSale1,766$0.98$1.7KForm 4
Nov 2, 2022MUEHL DANIEL WSee RemarksSale4,579$0.98$4.5KForm 4
Nov 2, 2022Rolfe LindseySee RemarksSale4,261$0.98$4.2KForm 4
Oct 3, 2022Harding Thomas C.See RemarksSale6$1.29$8Form 4
Sep 2, 2022Rolfe LindseySee RemarksSale2,545$1.20$3.1KForm 4
Sep 2, 2022Gross Paul EdwardSee RemarksSale2,308$1.20$2.8KForm 4
Sep 2, 2022Harding Thomas C.See RemarksSale1,616$1.20$1.9KForm 4
Sep 2, 2022IVERS-READ GILLIAN CSee RemarksSale2,234$1.20$2.7KForm 4
Sep 2, 2022MUEHL DANIEL WSee RemarksSale2,234$1.20$2.7KForm 4
Aug 2, 2022MUEHL DANIEL WSee RemarksSale4,654$1.46$6.8KForm 4
Aug 2, 2022Rolfe LindseySee RemarksSale4,330$1.46$6.3KForm 4
Aug 2, 2022IVERS-READ GILLIAN CSee RemarksSale3,802$1.46$5.6KForm 4
Aug 2, 2022Gross Paul EdwardSee RemarksSale4,807$1.46$7.0KForm 4
Aug 2, 2022Harding Thomas C.See RemarksSale1,809$1.46$2.6KForm 4
Jul 5, 2022Harding Thomas C.See RemarksSale7$2.71$19Form 4
Jun 2, 2022Harding Thomas C.See RemarksSale1,722$0.64$1.1KForm 4
Jun 2, 2022MUEHL DANIEL WSee RemarksSale2,327$0.64$1.5KForm 4
Jun 2, 2022Rolfe LindseySee RemarksSale2,650$0.64$1.7KForm 4

All 50 trades can be filtered by person here when JavaScript is on.

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

SEC filer profile

How Clovis Oncology is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARClovis Oncology, Inc.2
  • CIK0001466301
  • Employer ID (EIN)90-04753552
  • Filer statusLarge accelerated filer2
  • Incorporated inDelaware2
  • Fiscal year endsDecember 312
  • Industry code (SIC)2834 Pharmaceutical Preparations2
  • Business address5500 Flatiron Parkway, Suite 100, Boulder, CO 803012
  • Phone(303) 625-50002
  • Shares outstanding144,955,263 as of Nov 4, 202214
  • Public float$671.3M as of Jun 30, 20217
  • On EDGAR sinceJun 25, 20092
  • Filings952 in all: 4 (446), 8-K (129), SC 13G/A (82), 3 (43), SC 13G (39), 10-Q (33), 424B5 (18), DEFA14A (16)2
    All 42 form types

    10-K (11), DEF 14A (11), S-8 (11), S-8 POS (11), CORRESP (10), EFFECT (10), UPLOAD (9), 4/A (6), S-3 (6), SC 13D/A (6), CT ORDER (5), 5 (4), D (4), S-1/A (4), SC 13D (4), 8-K/A (3), FWP (3), PRE 14A (3), S-3ASR (3), 3/A (2), 424B1 (2), 424B3 (2), POS AM (2), POSASR (2), S-1 (2), S-3/A (2), 15-12G (1), 25-NSE (1), 8-A12B (1), CERTNAS (1), D/A (1), PRER14A (1), RW (1), S-3MEF (1)

  • Latest filingsAnnual report (10-K) Feb 24, 2022
    Quarterly report (10-Q) Nov 9, 2022
    Proxy statement (DEF 14A) Apr 27, 2022
    Latest 8-K (8-K) Jul 11, 2023

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40
  41. 41
  42. 42
  43. 43
  44. 44
  45. 45
  46. 46
  47. 47
  48. 48
  49. 49
  50. 50
  51. 51
  52. 52
  53. 53
  54. 54
  55. 55
  56. 56
  57. 57
  58. 58
  59. 59